Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining ‌gains brought by its blockbuster weight-loss drug Wegovy, ‌after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's ​rival. Novo, which in 2024 was worth more than $650 billion, has since shed around $475 billion, with the shares back at levels last seen before Wegovy transformed it into Europe's most ‌valuable drugmaker. Novo's shares ⁠fell to their lowest level s ...

Eli Lilly Gains as Novo Nordisk Trial SetbackNovo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema demonstrated a safe profile, the results did n ...

-- Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why [Stocks Lose Ground Amid Tariff Uncertainty][Trump's 'Plan B' on Tariffs: More Tariffs][Economy Grew Far Less Than Expected in Q4][Inflation Likely to Keep Fed from Cutting Rates Soon]- Top StoriesWith Monday's drop, Novo Nordisk shares have lost more than half their value in the last 12 months.Kristian Tuxen Ladegaard Berg / NurPhoto / Getty ImagesClose### Key Takeaways- Novo Nordisk's CagriSema, its next-generation weig ...

Novo Nordisk (NYSE: NVO) is taking it on the chin this morning, after revealing the latest clinical trial results for weight loss using its CagriSema drug (a 50-50 mix of amylin analog cagrilintide and Novo's glucagon-like peptide-1 (GLP-1) receptor agonist). After an 84-week trial, Novo reported that its patients achieved 23% weight loss with the drug. That sounds like pretty good news, but investors don't seem to like the number -- and as of 10:10 a.m. ET, Novo Nordisk stock is down 14.8%. Where to inve ...

Some analysts are worried that the artificial intelligence (AI) bubble will burst soon, causing a market crash. Whether or not there's something to these fears, it's a good idea for investors to buy shares of companies that can survive downturns and thrive long after. One stock I'd bet on right now is Eli Lilly (NYSE: LLY). Here's why. The leader in a fast-growing market Eli Lilly has historically been one of the largest players in the diabetes medicine market, and it remains so today. However, over the ...

记者丨黎雨桐 李益文 编辑丨倪新平 美国贸易政策前景不明令市场情绪承压，23日，美股三大指数集体低开，截至北京时间22：40，纳指跌 0.23%，道指跌0.05%，标普500指数跌0.02%。 | 美股指数 它 | | | | --- | --- | --- | | 道琼斯工业 | 纳斯达克指数 | 标普500 | | 49602.91 | 22833.70 | 6907.97 | | -23.06 -0.05% -52.37 -0.23% -1.54 -0.02% | | | | 美国科技七巨头 中概科技龙头 | | 中国金龙 | | 63149.24 | 4055.96 | 7568.77 | | -57.75 -0.09% +44.89 +1.12% +18.89 +0.25% | | | | 道琼斯期货 | 纳斯达克100期 | 标普500期货 | | 49495 | 24956.00 | 6904.00 | | -179 -0.36% -111.50 -0.44% -19.25 -0.28% | | | 科技股多数下跌，特斯拉跌超2%，亚马逊、微软跌近2%，脸书跌近1%。 欧洲减肥药巨头诺和诺德大跌 ...

诺和诺德(NVO.US)盘初大跌近16%，报39.97美元；礼来(LLY.US)盘初涨超4%，报1055.47美元。诺和诺 德称其减肥药物卡格列肽(Cagrisema)的实验效果不及礼来的替尔泊肽(Zepbound)。 ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE:LLY).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner spotted 26 ...

每经AI快讯，2月23日，礼来涨幅扩大至4.6%。 （文章来源：每日经济新闻） ...

本文源自：金融界AI电报 礼来(LLY.N)涨幅扩大至4.6%。 ...